Tagged with S

Ţuca Zbârcea & Asociaţii A lot of the opportunities and challenges in the pharma and healthcare sector of Romania depend on the overall Romanian business environment in the first place. How would you assess the overall attractiveness of the Romanian business environment for foreign companies? Romania’s overall business environment has improved significantly over the…

IMS Romania We understand that you have been heading IMS Health in Romania for 10 years now, which has been quite a trajectory. Therefore, can you highlight the key milestones and achievements for IMS Romania in this past decade? IMS is partner of choice for industry because of its combination of data…

Janssen Janssen recently signed memorandums of understanding with both the Skolkovo Foundation and ChemRar. Can you describe the strategic parameters and intended outcomes of these agreements? How do they factor into what seems to be an invigorated approach by this company to bring R&D to Russia? The idea to bring R&D…

GfK Rus Mr. Demidov, you are one of the pioneers of market research studies in Russia. There is a quote you like to use: ‘Market research is a business in the United States, an industry in Great Britain, a science in Germany, and an art in Russia.’ What are the specificities of…

National Health Insurance House of Romania (CNAS) If we first take a look at the healthcare system in Romania, it is clear that finding adequate funding has been a key challenge for many years. With 3.6% of GDP being spent on healthcare, Romania equals levels of countries such as Burundi and Bangladesh. In your view, what were…

Ferring Pharmaceuticals SA Representative Office in Romania Ferring is a company with a tremendous history dating back to the 1950s in Sweden. Now present in over 50 countries, the Group has managed to maintain a double digit annual growth over the last 2 decades. Focusing on Romania in particular, can you first of all tell us more…

CMS Russia How would you describe CMS’s own presence in the life sciences field in Russia, and what unique competitive advantages does the firm bring to this area of practice? Over the last five years, we have been truly active in the Russian life sciences market. In general, CMS has adopted a…

Servier Russia With the announcement of the Pharma 2020 strategy to develop the domestic pharmaceutical industry, multinational companies have pledged an excess of $1Bn in investment into local infrastructure. Servier, however, preempted this drive, and has had a Russian facility since 2007, the same year you took this position. Russia has traditionally…

Euroservice You founded Euroservice, and have managed this business since its inception in 1996. What are the key drivers that have facilitated the growth of this company from a staff of 6 people to the ninth-ranking importing distributor in this country? I believe that it is of some value, especially in…

Scottish Enterprise What does the life sciences sector represent for the Scottish economy in terms of value and employment and how have these figures evolved over the last few years? The Scottish government has set out an economic strategy in which they identify six key industrial sectors for the growth of the…

PAREXEL Russia PAREXEL prides itself on improving the time schedule of a product launch. What is the significance of time-to-market in the healthcare industry, and how can PAREXEL expedite the process better than its competitors? For pharma companies, time is always money—the tendency and drive, therefore, is to get products to market…

NAARI AG Russia/CIS Since our last report on Russia in 2007, there has been much emphasis placed on developing local industry, and reducing the nation’s reliance on imported pharmaceutical products. How do you believe the game has changed for foreign companies looking to play in Russia? Firstly, it is necessary to specify the…